Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr Elini Street, Cairo, 11562, Egypt.
Drug Deliv Transl Res. 2024 Jan;14(1):80-102. doi: 10.1007/s13346-023-01384-x. Epub 2023 Aug 4.
The objective of the current study was to create an efficient, minimally invasive combined system comprising in situ forming hydrogel loaded with both spray-dried polymeric nanoparticles encapsulating linezolid and nanohydroxyapatite for local injection to bones or their close vicinity. The developed system was designed for a dual function namely releasing the drug in a sustained manner for long-term treatment of bone infections and supporting bone proliferation and new tissues generation. To achieve these objectives, two release sustainment systems for linezolid were optimized namely a composite in situ forming chitosan hydrogel and spray-dried PLGA/PLA solid nanoparticles. The composite, in situ forming hydrogel of chitosan was prepared using two different gelling agents namely glycerophosphate (GP) and sodium bicarbonate (NaHCO) at 3 different concentrations each. The spray-dried linezolid-loaded PLGA/PLA nanoparticles were developed using a water-soluble carrier (PVP K30) and a lipid soluble one (cetyl alcohol) along with 3 types of DL-lactide and/or DL-lactide-co-glycolide copolymer using nano-spray-drying technique. Finally, the optimized spray-dried linezolid nanoparticles were incorporated into the optimized composite hydrogel containing nanohydroxy apatite (nHA). The combined hydrogel/nanoparticle systems displayed reasonable injectability with excellent gelation time at 37 °C. The optimum formulae sustained the release of linezolid for 7-10 days, which reveals its ability to reduce the frequency of injection during the course of treatment of bones infections and increase the patients' compliance. They succeeded to alleviate the bone infections and the associated clinical, biochemical, radiological, and histopathological changes within 2-4 weeks of injection. As to the state of art in this study and to the best of our knowledge, no such complete and systematic study on this type of combined in situ forming hydrogel loaded with spray-dried nanoparticles of linezolid is available yet in literatures.
本研究的目的是创建一种高效、微创的联合系统,该系统由原位形成的水凝胶组成,其中负载有同时包载利奈唑胺的喷雾干燥聚合物纳米粒和纳米羟基磷灰石,用于局部注射到骨骼或其附近。所开发的系统具有双重功能,即持续释放药物以进行长期的骨感染治疗,并支持骨增殖和新组织生成。为了实现这些目标,优化了两种用于利奈唑胺的释放维持系统,即复合原位形成壳聚糖水凝胶和喷雾干燥 PLGA/PLA 固体纳米粒。复合原位形成壳聚糖水凝胶是使用两种不同的凝胶剂甘油磷酸酯(GP)和碳酸氢钠(NaHCO),每种都有 3 种不同的浓度来制备的。喷雾干燥载利奈唑胺的 PLGA/PLA 纳米粒是使用水溶性载体(PVP K30)和脂溶性载体(鲸蜡醇)以及 3 种类型的 DL-丙交酯和/或 DL-丙交酯-乙交酯共聚物通过纳米喷雾干燥技术开发的。最后,将优化的喷雾干燥利奈唑胺纳米粒掺入含有纳米羟基磷灰石(nHA)的优化复合水凝胶中。复合水凝胶/纳米颗粒系统具有良好的可注射性,在 37°C 时具有优异的凝胶化时间。最佳配方可持续释放利奈唑胺 7-10 天,这表明其能够减少治疗骨感染过程中的注射频率,并提高患者的顺应性。它们成功地在 2-4 周的注射后缓解了骨感染及其相关的临床、生化、放射学和组织病理学变化。就本研究的现有技术水平以及我们的知识范围而言,在文献中尚未发现针对这种载有喷雾干燥利奈唑胺纳米粒的原位形成水凝胶的完整和系统的研究。